A citation-based method for searching scientific literature

Jason L Vassy, Sojeong Chun, Sanjay Advani, Sophie A Ludin, Jason G Smith, Elaine C Alligood. Clin Pharmacol Ther 2019
Times Cited: 11







List of co-cited articles
86 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
L B Ramsey, S G Johnson, K E Caudle, C E Haidar, D Voora, R A Wilke, W D Maxwell, H L McLeod, R M Krauss, D M Roden,[...]. Clin Pharmacol Ther 2014
226
81

SLCO1B1 variants and statin-induced myopathy--a genomewide study.
E Link, S Parish, J Armitage, L Bowman, S Heath, F Matsuda, I Gut, M Lathrop, R Collins. N Engl J Med 2008
54

Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings.
Bruce Peyser, Emily P Perry, Kavisha Singh, Rosalynn D Gill, Michael R Mehan, Susanne B Haga, Michael D Musty, Nicholas A Milazzo, Dillon Savard, Yi-Ju Li,[...]. Circ Genom Precis Med 2018
22
54

Pharmacogenomics knowledge for personalized medicine.
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin Pharmacol Ther 2012
956
45

The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
Catherine E de Keyser, Bas J M Peters, Matthijs L Becker, Loes E Visser, André G Uitterlinden, Olaf H Klungel, Céline Verstuyft, Albert Hofman, Anke-Hilse Maitland-van der Zee, Bruno H Stricker. Pharmacogenet Genomics 2014
37
36

Pharmacogenomics in the clinic.
Mary V Relling, William E Evans. Nature 2015
371
36

Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
Henry M Dunnenberger, Kristine R Crews, James M Hoffman, Kelly E Caudle, Ulrich Broeckel, Scott C Howard, Robert J Hunkler, Teri E Klein, William E Evans, Mary V Relling. Annu Rev Pharmacol Toxicol 2015
262
36

Phenotype standardization for statin-induced myotoxicity.
A Alfirevic, D Neely, J Armitage, H Chinoy, R G Cooper, R Laaksonen, D F Carr, K M Bloch, J Fahy, A Hanson,[...]. Clin Pharmacol Ther 2014
114
36

Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink.
Daniel F Carr, Ben Francis, Andrea L Jorgensen, Eunice Zhang, Hector Chinoy, Susan R Heckbert, Joshua C Bis, Jennifer A Brody, James S Floyd, Bruce M Psaty,[...]. Clin Pharmacol Ther 2019
17
36

Pharmacogenomics.
Dan M Roden, Howard L McLeod, Mary V Relling, Marc S Williams, George A Mensah, Josh F Peterson, Sara L Van Driest. Lancet 2019
102
36

Pharmacogenetics of Statin-Induced Myotoxicity.
Ping Siu Kee, Paul Ken Leong Chin, Martin A Kennedy, Simran D S Maggo. Front Genet 2020
8
50



Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study.
L A Donnelly, A S F Doney, R Tavendale, C C Lang, E R Pearson, H M Colhoun, M I McCarthy, A T Hattersley, A D Morris, C N A Palmer. Clin Pharmacol Ther 2011
130
27

Discontinuation of statins in routine care settings: a cohort study.
Huabing Zhang, Jorge Plutzky, Stephen Skentzos, Fritha Morrison, Perry Mar, Maria Shubina, Alexander Turchin. Ann Intern Med 2013
366
27


Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.
Kelly E Caudle, Teri E Klein, James M Hoffman, Daniel J Muller, Michelle Whirl-Carrillo, Li Gong, Ellen M McDonagh, Katrin Sangkuhl, Caroline F Thorn, Matthias Schwab,[...]. Curr Drug Metab 2014
219
27


2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Neil J Stone, Jennifer G Robinson, Alice H Lichtenstein, C Noel Bairey Merz, Conrad B Blum, Robert H Eckel, Anne C Goldberg, David Gordon, Daniel Levy, Donald M Lloyd-Jones,[...]. Circulation 2014
27

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
C Baigent, A Keech, P M Kearney, L Blackwell, G Buck, C Pollicino, A Kirby, T Sourjina, R Peto, R Collins,[...]. Lancet 2005
27

Pragmatic Trials in Genomic Medicine: The Integrating Pharmacogenetics In Clinical Care (I-PICC) Study.
Charles A Brunette, Stephen J Miller, Nilla Majahalme, Cynthia Hau, Lauren MacMullen, Sanjay Advani, Sophie A Ludin, Andrew J Zimolzak, Jason L Vassy. Clin Transl Sci 2020
5
60

Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.
Qingtao Hou, Sheyu Li, Ling Li, Yun Li, Xin Sun, Haoming Tian. Medicine (Baltimore) 2015
44
27

Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial.
Jason L Vassy, J Michael Gaziano, Robert C Green, Ryan E Ferguson, Sanjay Advani, Stephen J Miller, Sojeong Chun, Anthony K Hage, Soo-Ji Seo, Nilla Majahalme,[...]. JAMA Netw Open 2020
5
60

A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
Ye Zhu, James P Moriarty, Kristi M Swanson, Paul Y Takahashi, Suzette J Bielinski, Richard Weinshilboum, Liewei Wang, Bijan J Borah. Genet Med 2021
7
42

Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
Olivia M Dong, Stephanie B Wheeler, Gracelyn Cruden, Craig R Lee, Deepak Voora, Stacie B Dusetzina, Tim Wiltshire. Value Health 2020
16
27


Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee.
Jason L Vassy, Annjanette Stone, John T Callaghan, Margaret Mendes, Laurence J Meyer, Victoria M Pratt, Ronald M Przygodzki, Maren T Scheuner, Jessica Wang-Rodriguez, Steven A Schichman. Genet Med 2019
13
18

Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers.
Nicholas J Keeling, Meagen M Rosenthal, Donna West-Strum, Amit S Patel, Cyrine E Haidar, James M Hoffman. Genet Med 2019
28
18


Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease.
P Michael Ho, David J Magid, Susan M Shetterly, Kari L Olson, Thomas M Maddox, Pamela N Peterson, Frederick A Masoudi, John S Rumsfeld. Am Heart J 2008
403
18

Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network.
Nina R Sperber, Janet S Carpenter, Larisa H Cavallari, Laura J Damschroder, Rhonda M Cooper-DeHoff, Joshua C Denny, Geoffrey S Ginsburg, Yue Guan, Carol R Horowitz, Kenneth D Levy,[...]. BMC Med Genomics 2017
57
18

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.
J A Luzum, R E Pakyz, A R Elsey, C E Haidar, J F Peterson, M Whirl-Carrillo, S K Handelman, K Palmer, J M Pulley, M Beller,[...]. Clin Pharmacol Ther 2017
81
18

Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping.
J S Schildcrout, J C Denny, E Bowton, W Gregg, J M Pulley, M A Basford, J D Cowan, H Xu, A H Ramirez, D C Crawford,[...]. Clin Pharmacol Ther 2012
125
18


Balancing Contamination and Referral Bias in a Randomized Clinical Trial: An Application of Pseudo-Cluster Randomization.
Brian W Pence, Bradley N Gaynes, Nathan M Thielman, Amy Heine, Michael J Mugavero, Elizabeth L Turner, Evelyn B Quinlivan. Am J Epidemiol 2015
6
33

Pharmacogenetic Information in Clinical Guidelines: The European Perspective.
Jesse J Swen, Marga Nijenhuis, Mandy van Rhenen, Nienke J de Boer-Veger, Anne-Marie Buunk, Elisa J F Houwink, Hans Mulder, Gerard A Rongen, Ron H N van Schaik, Jan van der Weide,[...]. Clin Pharmacol Ther 2018
38
18

Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems.
L J Rasmussen-Torvik, S C Stallings, A S Gordon, B Almoguera, M A Basford, S J Bielinski, A Brautbar, M H Brilliant, D S Carrell, J J Connolly,[...]. Clin Pharmacol Ther 2014
146
18

Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Kelly E Caudle, Henry M Dunnenberger, Robert R Freimuth, Josh F Peterson, Jonathan D Burlison, Michelle Whirl-Carrillo, Stuart A Scott, Heidi L Rehm, Marc S Williams, Teri E Klein,[...]. Genet Med 2017
226
18

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
L R Brunham, P J Lansberg, L Zhang, F Miao, C Carter, G K Hovingh, H Visscher, J W Jukema, A F Stalenhoef, C J D Ross,[...]. Pharmacogenomics J 2012
129
18

Pharmacogenomics of statins: understanding susceptibility to adverse effects.
Joseph P Kitzmiller, Eduard B Mikulik, Anees M Dauki, Chandrama Murkherjee, Jasmine A Luzum. Pharmgenomics Pers Med 2016
41
18

Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.
Dan M Roden, Sara L Van Driest, Quinn S Wells, Jonathan D Mosley, Joshua C Denny, Josh F Peterson. Circ Res 2018
18
18

Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data.
Yitian Zhou, Kohei Fujikura, Souren Mkrtchian, Volker M Lauschke. Front Pharmacol 2018
35
18

Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact.
Cathelijne H van der Wouden, Paul C D Bank, Kübra Özokcu, Jesse J Swen, Henk-Jan Guchelaar. Genes (Basel) 2019
27
18

Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis.
Qian Xiang, Shu-Qing Chen, Ling-Yue Ma, Kun Hu, Zhuo Zhang, Guang-Yan Mu, Qiu-Fen Xie, Xiao-Dan Zhang, Yi-Min Cui. Pharmacogenomics J 2018
19
18

Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.
Chiara Fabbri, Katherine E Tansey, Roy H Perlis, Joanna Hauser, Neven Henigsberg, Wolfgang Maier, Ole Mors, Anna Placentino, Marcella Rietschel, Daniel Souery,[...]. Eur Neuropsychopharmacol 2018
27
18

Pharmacogenetics of antidepressant response: A polygenic approach.
Judit García-González, Katherine E Tansey, Joanna Hauser, Neven Henigsberg, Wolfgang Maier, Ole Mors, Anna Placentino, Marcella Rietschel, Daniel Souery, Tina Žagar,[...]. Prog Neuropsychopharmacol Biol Psychiatry 2017
43
18

Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?
Roos van Westrhenen, Katherine J Aitchison, Magnus Ingelman-Sundberg, Marin M Jukić. Front Psychiatry 2020
29
18

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.
Ran Wu, Yi-Ju Cheng, Li-Li Zhu, Lei Yu, Xue-Ke Zhao, Min Jia, Chang-Hui Wen, Xing-Zhen Long, Ting Tang, Ai-Juan He,[...]. Oncotarget 2016
21
18

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.
P Kuehl, J Zhang, Y Lin, J Lamba, M Assem, J Schuetz, P B Watkins, A Daly, S A Wrighton, S D Hall,[...]. Nat Genet 2001
18

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
Marja K Pasanen, Mikko Neuvonen, Pertti J Neuvonen, Mikko Niemi. Pharmacogenet Genomics 2006
345
18


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.